galloflavin | 568-80-9

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: galloflavin
• 英文别名: 3,8,9,10-tetrahydroxypyrano[3,2-c][2]benzopyran-2,6-dione；NSC 107022；3,8,9,10-tetrahydroxypyrano[3,2-c]isochromene-2,6-dione
• CAS: 568-80-9
• 化学式: C₁₂H₆O₈
• 分子量: 278.175
• InChiKey: VYKVZHXHVUVABA-UHFFFAOYSA-N

物化性质

• 熔点：
  >140°C (dec.)
• 沸点：
  727.6±60.0 °C(Predicted)
• 密度：
  2.10±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO：可溶，5mg/mL，澄清

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  134
• 氢给体数：
  4
• 氢受体数：
  8

安全信息

• 海关编码：
  2932999099
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302

反应信息

• 作为反应物：
  描述：

  galloflavin 在 氢氧化钾 作用下， 生成 7,8,9-trihydroxy-5-oxo-5H-furo[3,2-c]isochromene-2-carboxylic acid
  参考文献：
  名称：

  290.番黄素。第一部分

  摘要：

  DOI：

  10.1039/jr9520001583

文献信息

• Pancreatic cancer therapy and diagnosis
  申请人：Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts

  公开号：US10874685B2

  公开（公告）日：2020-12-29

  The present disclosure provides a novel method for treating pancreatic cancer and pancreatitis in which a combination of a dopamine receptor antagonist (pimozide, haloperidol, and/or L-741,626), 2-deoxy-D-glucose and atorvastatin are used, optionally in combination with gemcitabine.

  本公开提供了一种治疗胰腺癌和胰腺炎的新方法，其中使用多巴胺受体拮抗剂（匹莫齐特、氟哌啶醇和/或 L-741,626）、2-脱氧-D-葡萄糖和阿托伐他汀的组合，可选择与吉西他滨联合使用。
• Small Molecule Metal-Activated Protein Inhibition
  申请人：Guida Wayne Charles

  公开号：US20160287554A1

  公开（公告）日：2016-10-06

  A cancer treatment comprises the administration of a pro-drug compound identified by an in silico candidate identification screening. The pro-drug candidates are selected from a data base and calculations are carried out on the association of the pro-drug candidates to form a complex with a metal ion and a proteasome active site. The pro-drug inhibits the active site of the proteasome in the presence of the metal ion and has little or no effect in the absence of the metal ion. The pro-drug can be: 3,4-dihydroxybenzoic acid; galloflavin; 2-[(carbamoylsulfanyl)acetyl]amino}benzoic acid; 6,7-Dihydroxycoumaranone; 3,6-bis(hydroxymethyl)pyridazin-4(1H)-one; and 4′,5,7-trihydroxyisoflavone, for binding with copper ion and proteasome.
• Inhibition of Acetyl-CoA Metabolism for Treatment and Prevention of Immune System Diseases and Disorders
  申请人：Memorial Sloan Kettering Cancer Center

  公开号：US20190321314A1

  公开（公告）日：2019-10-24

  Provided are methods for treating or preventing T cell-mediated diseases or disorders by administering an inhibitor of acetyl-CoA production, such as an inhibitor of lactate dehydrogenase A or an inhibitor of ATP-citrate lyase.
• PANCREATIC CANCER THERAPY AND DIAGNOSIS
  申请人：Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts

  公开号：US20200030356A1

  公开（公告）日：2020-01-30

  The present disclosure provides a novel method for treating pancreatic cancer and pancreatitis. The disclosure pertains to antagonists of dopamine receptors, that when combined with a glycolysis inhibitor, and a cholesterol lowering agent inhibit the growth of pancreatic cells.
• COMPOSITIONS AND METHODS FOR TREATING OCULAR CONDITIONS
  申请人：The Regents of the University of California

  公开号：US20220079899A1

  公开（公告）日：2022-03-17

  Disclosed herein are methods for treating an ocular pathology in a subject, comprising administering to the subject an ENPP1 inhibitor. Also disclosed are methods of inhibiting ATP hydrolysis in ocular tissue, the method comprising contacting the ocular tissue with an ENPP1 inhibitor. Also provided herein are ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) inhibitors and compositions comprising the same.